Bristol Myers Squibb Reports Q2 Revenue Growth, Raises Full-Year Guidance
Bristol Myers Squibb (NYSE:BMY) reported second-quarter revenue of approximately $13 billion in 2026, a 5% increase from the prior year. The growth was driven by its newer products, which offset declines in legacy portfolio sales. The company raised full-year guidance for both revenue and adjusted earnings per share due to strong first-half performance. Key contributors included ELIQUIS, with revenue rising 21% to $4.5 billion, as well as REBLOZYL (+29%), BREYANZI (+41%), CAMZYOS (+59%), COBENFY (+81%), and Sotyktu ($261 million in Q2). The growth portfolio now accounts for nearly 60% of total sales. Legacy product revenue is expected to decline between 4% and 6%, a less severe drop than previously anticipated. Pipeline developments were also highlighted, with several key readouts delayed into 2027, including milvexian atrial-fibrillation data and COBENFY Alzheimer's psychosis results. The company remains focused on pipeline investment, business development, and AI partnerships to drive long-term growth.
Tickers: $BMY